* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. If you are pregnant, nursing, taking medication, or have a medical condition, consult your physician before using this product.

Golf Fuel Vitamins & Focus Drinks


  1. Burke, E. and Fahey T., Phosphatidylserine (PS):Promise for athletic performance. New Canaan, Ct. Keats Publishing, 1998.
  2. Crook, T., et al., “Effects of phosphatidylserine in age associated memory impairment,” Neurol 1991, 41:644-649. 
  3. Palmieri G., et al., “Double-blind controlled trial of phosphatidylserine in subjects with senile mental deterioration,” Clin. Trails J. 1987, 24:73-83.
  4. Monteleone, P., et al., “Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men,” Eur. J. Clin. Pharamacol. 1992, 41: 385-388.
  5. Monteleone, P., et al., “Effects of phosphatidylserine on the neuroendocrine responses to physical stress in humans,” Neuroendocrinol. 1990, 52: 243-248.
  6.  Fahey,et al., “The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Biol Sport. 1998, 15:135–144.
  7. Griffin J, Ojeda S. Textbook of endocrine physiology, 3rd ed. New York: Oxford University Press, 1996.
  8. Simmons, et al., “Increased proteolysis: an effect of increases in plasma cortisol within the physiological range,” J Clin Invest. 1984, 73 : 412-420.
  9. Baumeister J., et al. “Influence of phosphatidylserine on cognitive performance and cortical activity after induced stress,” Nutr Neurosci 2008, 11 (3): 103-110.


  1. Deijen JB, et al., “Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course,” Brain Res Bull (1999) 48 (2) :203-209.
  2. Neri DF, et al., “The effects of tyrosine on cognitive performance during extended wakefulness,” Aviat Space Environ Med (1995) 66 (4) : 313-319.
  3. Salter CA. “Dietary tyrosine as an aid to stress resistance among troops,” Mil Med (1989) 154 (3) : 144-146.
  4. Owasoyo JO, et al., “Tyrosine and its potential use as a countermeasure to performance decrement in military sustained operations,” Aviat Space Environ Med (1992) 63(5): 364-369.
  5. Deijen JB, Orlebeke JF, “Effect of tyrosine on cognitive function and blood pressure under stress,” Brain Res Bull. (1994) 33 (3):319-323.


  1. Osvaldo RE.  “2-Dimethylaminoethanol (Deanol): a brief review of its clinical efficacy and postulated mechanism of action,” Curr Ther Res 1980; 18: 1238-42.
  2. Fisman M, Mersky H, Helmes E. “Double-blind trial of 2-dimethylaminoethanol in Alzheimer’s disease,” Am J Psychiatry. 1981 138(7):970-2.
  3. Zahniser NR, Chou D, Hanin I. “Is 2-dimthylaminoethanol (deanol) indeed a precursor of brain acetylcholine? A gas chromatographic evaluation,” J Pharmacol Exp Ther . 1977;200:545-559.
  4. Davydova NG, et al., “[Effects of nootropic agents on visual functions and lacrimal antioxidative activity in patients with primary open-angle glaucoma],” Vestn Oftalmol. 2006 122 (6 ):42-45.
  5. Bonavita E. “[Neuropsychological study of the senile brain during and after single and combined treatment with deanol and citicoline],” Clin Ter. 1986 117(5):387-98.

Huperzine A

  1. Sun, Q, et al. “Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students,” Zhongguo-Yao-Li-Xue-Bao. 1999 20(7): 601-603
  2. Gordon, R K, et al., “The NMDA receptor ion channel: a site for binding of Huperzine A,” J-Appl-Toxicol. 2001 21 Suppl 1: S47-51
  3. Shang, Y Z, et al., “Improving effects of huperzine A on abnormal lipid peroxidation and superoxide dismutase in aged rats,” Zhongguo-Yao-Li-Xue-Bao. 1999 20(9): 824-828
  4. Wang, X D, et al., “Modulation of NMDA receptor by huperzine A in rat cerebral cortex,” Zhongguo Yao Li Xue Bao. 1999 20(1):31-35
  5. Ye, J W, et al.,”Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment,” Pharmacol-Exp-Ther. 1999 288(2): 814-819.
  6. Shi Q, et al., “Huperzine A ameliorates cognitive deficits and oxidative stress in the hippocampus of rats exposed to acute hypobaric hypoxia,” Neurochem Res. 2012 37(9):2042-2052.


  1. Sangeeta R., et al. “Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment,” Indian J Psychiatry  2006  48(4): 238–242.
  2. Stough C., et al. “Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial,” Phytother Res. 2008 Dec;22(12):1629-34.
  3. Stough C, et al. “The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects,” Psychopharmacology (Berl). 2001 156 (4):481-484.
  4. Das A, et al. “A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: anticholinesterase and cognitive enhancing activities,” Pharmacol Biochem Behav. 2002 73(4):893-900.
  5. Singh M, et al.,“Neuroprotective mechanisms of the standardized extract of Bacopa monniera in a paraquat/diquat-mediated acute toxicity,” Neurochem Int. 2013 62(5) : 530-539.

Ginkgo Biloba

  1. Birks J,et al. “Ginkgo biloba for cognitive impairment and dementia.” Cochrane Database Syst Rev 2007 (2):CD003120.
  2. Carlson JJ, et al. “Safety and efficacy of a ginkgo biloba-containing dietary supplement on cognitive function, quality of life, and platelet function in healthy, cognitively intact older adults,” J Am Diet Assoc 2007  107(3):422-432.
  3. Lovera J, et al. “Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial,” Mult Scler 2007 13(3):376-385.
  4. Napryeyenko O, et al., “Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial,” Arzneimittelforschung 2007;57(1):4-11. .
  5. Defeudis F., et al. “Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications,” Curr Drug Targets. 2000 1(1):25-58.


  1. Wahlstrom D, et al., “The effect of acute tyrosine phenylalanine depletion on emotion-based decision-making in healthy adults,” Pharmacol Biochem Behav. 2013 105:51-57.
  2. Wood DR, et al.,“Treatment of attention deficit disorder with DL-phenylalanine,” Psychiatry Res. 1985 16(1):21-26.
  3. Beckmann H, et al.,“[DL-phenylalanine as an antidepressant. Open study (author’s transl)],” Arzneimittelforschung. 1978;28(8):1283-1284.
  4. Beckmann H, et al.“Dl-phenylalanine in depressed patients: an open study,” J Neural Transm. 1977; 41 (2-3): 123-134.
  5. Reuss S, et al., “Phenylalanine and UVA for Vitiligo patients: probability of an effective treatment,” Med Hypotheses. 2006 67(1):199-200.


  1. Huxtable RJ “Physiological actions of taurine,” Physiol Rev. 1992  72(1):101-163.
  2. Bouckenooghe T, et al., “Is taurine a functional nutrient?” Curr Opin Clin Nutr Metab Care. 2006 9(6):728-733.
  3. Szymański K., et al. “[Taurine and its potential therapeutic application],” Postepy Hig Med Dosw (Online). 2008 62:75-86
  4. Kendler BS “Taurine: an overview of its role in preventive medicine,” Prev Med. 1989  (1):79-100.
  5. Birdsall TC “Therapeutic applications of taurine,” Altern Med Rev. 1998 (2):128-136.


Cetyl Myristoleate (CMO) References

  1. Barathur R., et al., “Cetylated fatty acids improve knee function in patients with osteoarthritis,” J Rheumatol. 2002 29 (8):1708-1712.
  2. Diehl HW, et al., “Cetyl myristoleate isolated from Swiss albino mice: an apparent protective agent against adjuvant arthritis in rats,” J Pharm Sci. 1994 83 (3):296-299.
  3. Barathur R, et al. A fatty acid ester complex (CMC) improves quality of life outcomes in osteoarthritis (OA) patients. FASEB J 2001;15:A265.

  4. Siemandi H. “The effect of cis-9-cetyl myristoleate (CMO) and adjunctive therapy on Arthritis and Auto-Immune Disease,” Townsend Letter for Doctors and Patients 1997 Aug/Sep; 58-63.
  5. Gault RA, et al., “Synthesis of cetyl myristoleate and evaluation of its therapeutic efficacy in a murine model of collagen-induced arthritis,” Pharmacol Res. 2003  47(1):43-47.